BARDA backs Medicines/Rempex antibiotic with $90m award

The Biomedical Advanced Research and Development Authority (BARDA) has awarded Rempex Pharmaceuticals, a wholly owned subsidiary of The Medicines Company (MDCO), a contract worth up to $90m to support the development of its investigational antibiotic Carbavance to treat antibiotic-resistant infections and act as an agent against two bioterrorism threats – melioidosis and glanders, two highly deadly infections.